The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | The changing role of autoSCT in DLBCL with the advent of novel immunotherapies
In this video, Chris Fox, MBChB(Hons), MRCP, FRCPath, Nottingham University Hospitals NHS Trust – City Campus, Nottingham, UK, briefly comments on the evolving role of autologous stem cell transplantation (autoSCT) in the treatment of diffuse large B-cell lymphoma (DLBCL) with the advent of novel immunotherapies, namely CD19-directed CAR T-cell therapy. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So traditionally the role of autologous stem cell transplant was for patients with chemosensitive first relapse of diffuse large B-cell lymphoma. But of course we’ve had two big randomized trials, ZUMA-7 with axi-cel, Transform with liso-cel, that have both challenged the role of autologous transplant specifically for those patients who relapse within 12 months having completed their first line therapy...
So traditionally the role of autologous stem cell transplant was for patients with chemosensitive first relapse of diffuse large B-cell lymphoma. But of course we’ve had two big randomized trials, ZUMA-7 with axi-cel, Transform with liso-cel, that have both challenged the role of autologous transplant specifically for those patients who relapse within 12 months having completed their first line therapy. So, this is a higher risk group, patients who are either primary refractory or have an early relapse. And in those two randomized data sets, there was superiority both in terms of event-free survival and overall survival with respect to ZUMA-7 data, for liso-cel and axi-cel, respectively. And so this led to regulatory approval, and many territories around the world now have access to the CD19-directed CAR-T products for those groups of patients who relapse within 12 months of first-line therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: AbbVie, Arvinas, BMS, GenMab, Gilead/Kite, Incyte, Morphosys, Ono, Roche, SERB, SOBI; Speaker honoraria: AbbVie, Gilead/Kite, Incyte, Roche, SERB; Research funding to Institution from Beigene, Incyte, Abbvie/Genmab.
